A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Condition(s):Metastatic Pancreatic Cancer; Nonresectable Pancreatic CancerLast Updated:October 28, 2005Completed
Hide Studies Not Open or Pending
Condition(s):Metastatic Pancreatic Cancer; Nonresectable Pancreatic CancerLast Updated:October 28, 2005Completed
Condition(s):Metastatic Pancreatic CancerLast Updated:June 18, 2019Unknown status
Condition(s):Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic CancerLast Updated:October 31, 2019Terminated
Condition(s):Pancreatic CancerLast Updated:June 2, 2023Completed
Condition(s):Metastatic Pancreatic CancerLast Updated:March 28, 2024Terminated
Condition(s):Pancreatic Neoplasms; Neoplasm Metastasis; Liver MetastasesLast Updated:June 27, 2023Active, not recruiting
Condition(s):Metastatic Pancreatic CancerLast Updated:October 18, 2023Terminated
Condition(s):Pancreas CancerLast Updated:September 15, 2023Terminated
Condition(s):Pancreatic NeoplasmsLast Updated:October 20, 2022Recruiting
Condition(s):Pancreatic CancerLast Updated:February 20, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.